BioSpace News Archive

Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief Executive Officer, will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference on September 13th at 4:30 p.m. Eastern time.

Benitec Biopharma Inc. announced the pricing of its underwritten public offering of 29,809,471 shares of its common stock and accompanying warrants to purchase up to 29,809,471 shares of common stock.

Codiak BioSciences, Inc. announced the pricing of its underwritten public offering of 13,333,333 shares of its common stock and accompanying warrants to purchase 13,333,333 shares of common stock, at a combined public offering price of $1.50 per share, together with accompanying warrants, for gross proceeds of approximately $20 million, before deducting underwriting discounts and commissions and offering expenses.

According to Nova one advisor, the global Pharmacogenomics market was valued at USD 15.2 billion in 2021 and it is expected to hit around USD 36.7 billion by 2030 with a CAGR of 10.29% during the forecast period 2022 to 2030.

Single Cell Analysis Systems are used majorly in research institutes and pharmaceutical, biotechnological and in-vitro studies for screening of cells, to find out the reproduction, mutation and death of cells.

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the Company’s ongoing U.S. Phase 2/3 clinical trial to evaluate the safety and efficacy of Tempol as a treatment for COVID-19 has reached the initial planned enrollment of 248 subjects.

Cano Health Inc. (“Cano” or the “Company”) (NYSE: CANO), a leading value-based primary care provider and population health company, today announced it will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022.

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced clinical updates from two wholly owned programs, ALPN-303 and davoceticept.

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today presented preliminary results from the company’s Phase 1 clinical trial evaluating zanidatamab zovodotin (ZW49) for the treatment of HER2-positive tumors.

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that the Japanese Ministry of Health, Labour and Welfare (JMHLW) approved reimbursement of EPIFIX® to treat refractory or hard-to-heal lower extremity diabetic and venous ulcers.